Kirsten Guerra

Bill Mann, a Motley Fool analyst with a keen eye on industrial espionage, reveals the alarming tactics in the semiconductor industry, including a case where secrets were stolen to build a competing chip plant. He explores the challenges of keeping corporate secrets secure. Joining him, Kirsten Guerra discusses Vertex Pharmaceuticals and its groundbreaking treatments for cystic fibrosis, highlighting the company's dominance and the complexities of drug development. They delve into the competitive landscape and the impact of potential generics on Vertex's future.